Cabaletta Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $223.72M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $-0.34 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $-0.39 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | – | $-0.44 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | $-0.65 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.56 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-0.51 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | $-0.46 | – |
Press releases
Announcements Cabaletta Bio filed with the SEC
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation June 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation May 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Corporate Presentation April 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Cabaletta Bio Announces 2026 Strategic Priorities
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation January 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases
Other events · EX-99.1 to Form 8-K
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases
Regulation FD disclosure · EX-99.1 to Form 8-K
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cabaletta Bio Announces Pricing of Public Offering of Securities
Material agreement · Other events · EX-99.1 to Form 8-K
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and
Agreement terminated · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection
Agreement terminated · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cabaletta Bio Announces Updated Clinical Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cabaletta Bio Announces Updated Clinical Data
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corporate Presentation JANUARY 2025 © 2025 Cabaletta Bio. All rights reserved.
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Phase 1/2 Trials NOVEMBER 2024 © 2024 Cabaletta Bio. All rights reserved.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
University of North Carolina, Chapel Hill, NC www.cabalettabio.com/technology/posters-publications Background Results SLE-1 SLE-2 LN-1 DM-1 IMNM-1 IMNM-2 SSc-Skin-1 CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
CABA-201 Initial Clinical Data from
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K